Figure 5.

Nb157 CAR T cells display antitumor activity in patient-derived AML cells in an NSG mouse model. Nb157 (A) and Nb163 (B) recognized PD AML cells by flow analysis. Nb157 (C) and Nb163 (D) CAR T cells specifically killed PD AML cells in vitro in a dose-dependent manner (n = 4). (E) Nb157 CAR T cells efficiently prolonged survival of NSG mice bearing PD AML. In brief, 20 million PD AML cells were injected into NSG mice, followed by treatment with 3 million Nb157 CAR T cells or UTD T cells, and survival of mice was monitored (n = 10, each group). (F-I) PD AML in NSG bone marrow and spleen was monitored after Nb157 CAR T cell treatment by staining with anti-human CD45/CD3/CD33, followed by flow cytometry analysis (n = 3). (J-K) At the end points of each group of experiments, mice spleens were harvested and fixed with paraformaldehyde, followed by immunofluorescence staining of anti-human CD3(red)/CD33(green) and DAPI (blue; nuclear).